"Hemoperfusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Removal of toxins or metabolites from the circulation by the passing of blood, within a suitable extracorporeal circuit, over semipermeable microcapsules containing adsorbents (e.g., activated charcoal) or enzymes, other enzyme preparations (e.g., gel-entrapped microsomes, membrane-free enzymes bound to artificial carriers), or other adsorbents (e.g., various resins, albumin-conjugated agarose).
| Descriptor ID |
D006464
|
| MeSH Number(s) |
E02.912.430 E04.292.510
|
| Concept/Terms |
Hemoperfusion- Hemoperfusion
- Hemoperfusions
- Hemosorption
- Hemosorptions
|
Below are MeSH descriptors whose meaning is more general than "Hemoperfusion".
Below are MeSH descriptors whose meaning is more specific than "Hemoperfusion".
This graph shows the total number of publications written about "Hemoperfusion" by people in this website by year, and whether "Hemoperfusion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 8 | 0 | 8 |
| 2018 | 4 | 2 | 6 |
| 2019 | 1 | 1 | 2 |
| 2020 | 11 | 1 | 12 |
| 2021 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Hemoperfusion" by people in Profiles.
-
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? Authors' response. J Crit Care. 2021 12; 66:31-32.
-
Reply: Does adjunctive hemoadsorption with CytoSorb® affect survival of COVID-19 patients on ECMO? A critical statement. J Crit Care. 2021 12; 66:189-190.
-
Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? A critical statement. J Crit Care. 2021 12; 66:187-188.
-
Investigation of plasma exchange and hemoperfusion effects and complications for the treatment of patients with severe COVID-19 (SARS-CoV-2) disease: A systematic scoping review. J Med Virol. 2021 Oct; 93(10):5742-5755.
-
Possibility of PMX-DHP therapy as a principal strategy against cytokine storm in COVID-19: Insights from reconstructed coagulation data. J Clin Apher. 2021 Oct; 36(5):785-786.
-
Hemoadsorption in critically ill patients with or without COVID-19: A word of caution. J Crit Care. 2021 10; 65:140-141.
-
Hemadsorption as a Treatment Option for Multisystem Inflammatory Syndrome in Children Associated With COVID-19. A Case Report. Front Immunol. 2021; 12:665824.
-
Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure. Respir Med. 2021 Aug-Sep; 185:106477.
-
Evaluating the elimination status of medications used for COVID-19 during hemoperfusion and therapeutic plasma exchange: A review. Int Immunopharmacol. 2021 Aug; 97:107707.
-
Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia. Blood Purif. 2022; 51(1):47-54.